Lightner AL, et al. - In this study, experts aspired to compare 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients vs those who had received TNFα inhibitors or no biologic therapy. A significantly higher 30-day postoperative surgical site infection was observed in 26% of Crohn's disease patients who received vedolizumab within 12 weeks prior to a major abdominal operation than that of patients receiving TNFα inhibitors or no biologic therapy. In multivariable analysis, vedolizumab within 12 weeks of surgery remained a predictor of 30-day postoperative surgical site infection. Even though vedolizumab-treated Crohn's disease patients could be a sicker cohort of patients, it was essential to consider these findings with regard to preoperative counselling, operative timing and primary closure of wounds.